As both the immune system and the blood-brain barrier (BBB) are likely to be developmentally immature in the perinatal period, neonatal gene transfer may be useful for the treatment of lysosomal storage disease (LSD) with neurological involvements such as metachromatic leukodystrophy (MLD). In this experiment, we examined the feasibility of single-strand adeno-associated viral serotype-9 (ssAAV9)-mediated systemic neonatal gene therapy of MLD mice. ssAAV9 vector expressing human arylsulfatase A (ASA) and green fluorescent protein (GFP) (ssAAV9/ASA) was injected into the jugular vein of newborn MLD mice. High levels of ASA expression were observed in the muscle and heart for at least 15 months. ASA was continuously secreted into plasma without development of antibodies against ASA. Global gene transfer into the brain and spinal cord (SC), across the BBB, and long-term ASA expression in the central nervous system were detected in treated mice. Significant inhibition of the accumulation of sulfatide (Sulf) in the brain and cervical SC was confirmed by Alcian blue staining and biochemical analysis of the Sulf content. In a behavior test, treated mice showed a greater ability to traverse narrow balance beams than untreated mice. These data clearly demonstrate that MLD mice model can be effectively treated through neonatal systemic injection of ssAAV9/ASA.
INTRODUCTION
Metachromatic leukodystrophy (MLD) is an inherited, autosomal recessive lysosomal storage disease (LSD) caused by a deficiency in the lysosomal enzyme arylsulfatase A (ASA), which catalyzes the degradation of galactosyl-3-sulfate ceramide (sulfatide (Sulf)), a major myelin sphingolipid. 1 This disease is characterized pathologically by myelin degeneration in both the central nervous system (CNS) and peripheral nervous system, and clinically by progressive motor and mental deterioration that is ultimately fatal. The main goal of treatment, therefore, is to arrest or reverse the progression of the neurological symptoms.
As lysosomal enzymes can be taken up by the cells through the mannose-6 phosphate receptor, 2,3 the first-line treatment for LSDs is enzyme replacement therapy (ERT). Many LSDs have been successfully treated by systemic infusion of recombinant enzymes. 4 However, ERT is often hampered by an immune reaction to the lysosomal enzyme. 5, 6 Antibodies can have adverse effects, including hypersensitivity/anaphylactic reactions, enzyme inactivation and enzyme degradation. Another problem of ERT is that the enzyme cannot cross the blood-brain barrier (BBB). Thus, ERT is effective for treatment of visceral organs, but not the CNS. 2 Surprisingly, some benefits of ERT on the nervous system function have been observed in MLD mice. 7, 8 However, a phase I/II clinical trial of ERT for MLD patients was reportedly unsuccessful (NCT00681811; http://www.clinicaltrials.gov).
As alternative strategies, a number of gene therapy protocols have been proposed to treat MLD. We have previously shown that a single injection of adeno-associated viral (AAV) vector expressing ASA into the brain parenchyma of ASA knockout (MLD) mice results in the wide distribution of ASA in the brain and the correction of biochemical and neurological phenotypes. 9 However, to apply this approach for large animals, including humans, multiple vector injections with invasive surgical trepanation of the skull are required. 10, 11 Another approach is transplantation of gene-corrected hematopoietic stem cells. It is suggested that some of the transplanted hematopoietic stem cells can cross the BBB to differentiate into microglial cells in the brain and secrete ASA throughout the brain. 12, 13 A phase I/II clinical trial of ex vivo gene therapy, using lentiviral vector transduced hematopoietic stem cells, has been initiated for pre-symptomatic or early symptomatic MLD patients (NCT01560182; http://clinicaltrials. gov). In these trials, the patients showed stable engraftment of the transduced hematopoietic stem cells and high expression levels of functional MLD gene. 14 The safety of this protocol related to the myeloablative conditioning regimen used and the use of an integrating lentiviral vector is now being evaluated.
Neonatal gene therapy may be a promising approach to treat MLD, because both the immune system and the BBB are developmentally immature during the perinatal period. It was recently demonstrated that AAV serotype-9 (AAV9) vector can cross the BBB of newborn mice, although its molecular mechanism is not clear at this time. Foust et al. 15 reported that a single intravenous injection of self-complementary AAV9 vector into newborn mice provided gene transfer into the CNS. We also showed global gene transfer into the CNS after neonatal systemic delivery of single-strand AAV (ssAAV) vectors including AAV9 vector. 16 In this study, we assessed the feasibility of neonatal gene therapy for MLD mice, mediated by intravenous administration of ssAAV9 vector to treat the neurological symptoms.
RESULTS
Expression of ASA after neonatal gene transfer ssAAV9 vector encoding human ASA and green fluorescent protein (GFP) (ssAAV9/ASA; 2 × 10 12 vg) was injected into the jugular vein of neonatal MLD mice. Enzyme-linked immune sorbent assay showed that the concentration of plasma human ASA rapidly increased to very high levels (~30 ng ml -1 ) at 2 weeks after injection but declined with animal growth until 8 weeks of age, with stable levels thereafter for at least 15 months (~7 ng ml -1 ; Figure 1a ). The distribution of ASA protein in seven organs was also investigated by enzyme-linked immune sorbent assay, 15 months after injection (Figure 1b) . The highest levels of ASA expression were detected in the heart (H) and skeletal muscle (M); however, substantial expression was also detected in the whole brain (B; 77.2 ± 17.3 ng mg -1 protein) and cervical spinal cord (SC; 21.7 ± 2.0 ng mg -1 protein), which indicates that ssAAV9 vector can cross the BBB of neonatal mice and stably transduce the CNS, as reported previously. 16 These results indicate that neonatal injection of ssAAV9/ASA results in long-term expression of ASA in both visceral organs and the CNS without antibody formation.
Efficient ASA expression throughout the brain The biodistribution of GFP and ASA in the CNS was assessed based on immunohistochemical staining after injection into the jugular vein of neonatal MLD mice. Fifteen months after vector injection, extensive expression of both GFP and ASA was detected throughout the brain, particularly in the cerebral cortex, hippocampus and cerebellum ( Figure 2 ). The olfactory bulb and brain stem were also efficiently transduced. As previously reported, immunostaining with specific antibodies showed that the vast majority of transduced cells were NeuN-positive neurons or calbindin-positive purkinje cells in the cerebellum (data not shown). 16 Close examination of immunostained pictures showed that most ASApositive cells were also GFP positive.
Efficient ASA expression in the SC Progressive demyelination occurs not only in the brain but also the SC in human MLD patients. We therefore also used immunohistochemical staining to assess ASA expression in the cervical SC of MLD mice. We found that transduction and efficient ASA expression were widespread in the cervical SC 15 months after systemic administration (Figure 3a ). In addition, neurons positive for NeuN, a neuronal marker, and choline acetyltransferase, a marker of motor neurons, were efficiently transduced in ssAAV9/ASA-treated mice (Figure 3b ). These results indicate that a single intravenous injection of ssAAV9/ASA is also sufficient for prolonged ASA expression in the SC.
Correction of Sulf storage and Sulf/GalC ratios in the CNS To assess the therapeutic effects of the ssAAV9-mediated neonatal gene therapy on MLD mice, we stained tissue samples with Alcian blue to detect the presence of Sulfs, which specifically accumulate in various tissues in MLD. In 15-month-old untreated MLD mice, Sulf was especially detectable in the white matter, including the corpus callosum, hippocampal fimbria, mid brain, medullary body, brain stem (Figure 4a ), and the ventral horn and white matter of the SC (Figure 4d Sulf and galactosylceramide (GalC) were quantified by thin-layer chromatography of the lipid extracts. Sulf storage in the brain was evaluated by the ratio of Sulf to GalC, which is a major component in the myelin sheath of oligodendrocytes. Sulf/GalC ratios were significantly diminished in the brain (0.18 ± 0.01 vs 0.55 ± 0.05, P = 0.0001; Figure 4g ) and cervical SC (0.26 ± 0.03 vs 0.48 ± 0.03, P = 0.0002) of ssAAV9/ASA-treated MLD mice ( Figure 4h ). These ratios of treated mice are comparable to those of age matched WT control mice (Figures 4g and h ).
Therapeutic effects of ssAAV9/ASA administration on neonatal MLD Finally, to assess the behavioral effects of neonatal ssAAV9/ASA administration on MLD mice, we subjected the mice to a balance beam test, as previously described.
12 ssAAV9/ASA-treated mice showed a greater ability to traverse narrow balance beams than untreated mice (latency: 9.4 ± 0.5 s vs 12.7 ± 0.9 s, P o0.03; number of slips: 2.6 ± 0.4 vs 5.2 ± 0.6, P o0.05; Figures 5a and b) . These results suggest that a single administration of ssAAV9/ASA to neonatal MLD mice improves motor function of MLD. Although, the number of slips did not recover to the normal level, significantly improved performance was observed after neonatal gene therapy.
DISCUSSION
Long-term secretion of the therapeutic protein is a basic strategy of gene therapy for treating various genetic diseases, including LSDs. This is an advantage of viral vector-mediated ERT over classical ERT, which requires repeated injections of costly recombinant protein.
The duration of gene expression is influenced by various factors, Figure 1 . Expression of ASA after neonatal gene transfer. ssAAV9/ASA was administered to neonatal MLD mice through the external jugular vein. (a) ASA in plasma. Blood was collected at 2, 4, 8, 12, 24 weeks and 15 months after injection and the concentration of plasma ASA was measured by enzyme-linked immune sorbent assay (ELISA; n = 6). (b) ASA in organs. ASA levels in selected organs were measured by ELISA 15 months after injection (n = 6). B, brain; H, heart; hASA, human arylsulfatase A; K, kidney; Li, liver; Lu, lung; M, muscle.
including the choice of the vector and the promoter, the route of vector administration, the target organ to be transduced and the age of animals. We showed that a long-term ERT can be achieved by a single intravenous injection of ssAAV9/ASA into neonatal mice. The CAG promoter used in our construct has been shown to provide ubiquitous and long-term expression in many organs including the brain. In our previous study using GFP, expression was mainly detected in the heart and muscle 1-month after neonatal intravenous injection. 16 Here, we confirmed that gene expression in heart and muscle remained very active 15 months after neonatal injection. It was reported that serotype 8 AAV (AAV8) or AAV9 vector efficiently transduced both neonatal and adult liver, but the gene expression is only transient in neonatal liver. 17 The rapid decline of gene expression in the neonatal liver could be due to dilution and degradation of episomal vector genomes during active cell mitosis. Post-mitotic tissues such as the muscle, heart and brain are important targets for AAVmediated neonatal gene therapy for long-term expression.
A single intravenous injection of ssAAV9 vector to neonates efficiently improves the biochemical and neurological abnormalities of MLD mice. The success of this approach is primarily dependent upon the global gene transfer into the CNS across the BBB. ASA expression was detected mainly in neuronal cells in the cerebral cortex, hippocampus, cerebellum, olfactory bulb and brain stem after neonatal gene therapy. In contrast, progressive accumulation of Sulf was most prominent in oligodendrocytes and microglial cells in the white matter. 18 These glial cells are resistant to AAV-mediated transduction. Nevertheless, Sulf accumulation in a few isolated areas of the brain was efficiently inhibited, suggesting that ASA molecules are secreted from the transduced neuronal cells and taken up by the distant glial cells.
Although we used single AAV vector expressing both ASA and GFP, we found ASA-positive, GFP-negative or ASA-negative, GFPpositive cells after immunohistochemical analysis. These substantial mismatch of GFP and ASA labeling were detected mainly in the dorsal horn (Figure 3a) . We speculate that potential sources of this mismatch arise from in vivo cross-correction of ASA enzyme (ASA-positive, GFP-negative cells), promoter to express proteins (CAG promoter for ASA, B19 promoter for GFP), characteristics of the proteins such as half-life and localization, and so on.
We demonstrated that ssAAV-mediated gene transfer in neonatal mice has various characteristics that may overcome the problems encountered in current gene therapy protocols. However, before applying neonatal gene transfer to humans, several specific points should be considered. First, the safety of neonatal gene transfer, particularly the possibility of germ line transmission, must be carefully evaluated using large animal models including nonhuman primates. The difference in developmental stages of each organ in mice and humans may be another problem. 19, 20 The immune system of mice is less mature at birth than those of large animals. It has been stated that the human BBB is functionally mature before birth. However, AAV9 may be able to bypass the mature human BBB during the neonatal period through receptormediated transcytosis mechanisms, although the exact mechanism by which AAV pass through the BBB is not clear at present.
In this study, we used ASA and GFP double expressing AAV vector. Recently, Ciesielska et al. 21 reported that AAV9 transduces antigen-presenting cells and this is a pretty effective way of generating anti-GFP antibodies and cell-mediated destruction of transduced cells. Moreover, it was also reported that fluorescent proteins expressed in cells per tissues can modify their molecular composition and cellular activities. [22] [23] [24] [25] These results suggest that GFP marker gene is not suitable for human gene therapy. Now, we are analyzing the effect of neonatal gene therapy for MLD using self-complementary AAV 9 vector expressing only ASA for clinical trial.
Another immunological concern is the host immune response to AAV capsid mediated by either circulating antibodies or cytotoxic T cells. AAV antibodies are present in human infants 26 with a high prevalence and titers decline from a mean of about 1:20 over the first 6 months of life whereupon they begin rise as children are exposed to AAV in the environment. Low AAV titers are often discounted as potentially inhibitory to intravenous transduction. However, anti-AAV titers of o 1:10 are remarkably capable of substantially blocking transduction of mouse liver by AAV2. 27 Therefore, to see how intravenous AAV9 works in the off-spring of mothers previously immunized with AAV9 empty vector should be evaluated using large animal. A recent survey in a healthy population from France showed that serum immunoglobulin G and neutralizing factors to AAV9 is less prevalent when compared with AAV1 and AAV2. 28 Possible strategies to overcome preexisting humoral immunity to AAV were recently discussed. 29 Regarding cell-mediated immunity, an initial trial of AAV2-mediated gene therapy for hemophilia B resulted in only transient expression of factor IX accompanied by a self-limited transaminase elevation, suggesting that transduced hepatocytes were destroyed by capsid specific CTL. 30 However, the recent success in long-term expression of factor IX after intravenous injection of scAAV8 vector suggests that CTL responses could be controlled or at least ameliorated by using optimized AAV vector and a short course of steroids. 31 The type and magnitude of the immunological response to AAV vector appear to be influenced by various factors including serotype of AAV. Further comprehensive clinical studies will be required to overcome the immunological barriers for successful gene therapy.
In summary, we clearly demonstrated that intravenous infusion into the neonatal MLD mice of ssAAV9 vector containing the ASA complementary DNA driven by the CAG promoter resulted in long-term secretion of ASA, widespread transduction of the brain and SC, and correction of biochemical and neurological abnormalities. ssAAV9-mediated neonatal gene therapy appears to be a promising approach to treating LSDs with neurological involvements.
MATERIALS AND METHODS Mice
ASA knockout (MLD) mice were obtained from the laboratory of Dr V Gieselmann. 32 These mice have been extensively characterized and are widely used as a model of MLD.
2,18,33-35 C57BL/6 mice were used as WT control mice. All animal experiments were performed in accordance with the regulations of the Ethics Committee of Nippon Medical School.
Production of AAV vectors
The recombinant AAV vector plasmid pAAV/ASA, which contained complementary DNA encoding C-terminal Flag-tagged human ASA driven by the CAG promoter and GFP driven by the B19 promoter, as described previously.
36 AAV9 packaging plasmids (p5E18VD2/9) were kindly provided from Dr J Wilson. 37 Recombinant ssAAV vectors were generated using a three-plasmid co-transfection system. Briefly, the AAV vector plasmid, the packaging plasmid (p5E18VD2/9) and a helper plasmid (pHelper; Stratagene, La Jolla, CA, USA) were co-transfected into HEK293 cells at a ratio of 1:1:1 under calcium phosphate precipitation. After 6 h of transfection, medium was replaced by fresh culture medium and cells were incubated for 50-60 h at 37°C under 5% CO 2 . Cells were dislodged from culture dishes and pelleted by centrifugation, then resuspended in phosphate-buffered saline, freeze-thawed three times. Cell debris was spin down at 3000 r.p.m. for 20 min at 4°C. AAV vectors were purified by ammonium sulfate precipitation and iodixanol continuous gradient centrifugation. 38, 39 The titer of ssAAV9/ASA vector was determined using real-time PCR (7500 Fast, Applied Biosystems, Tokyo, Japan).
Intravenous injection
Neonatal (within the first 48 h of life) MLD mice were positioned by hand and ssAAV9/ASA vector were administered via the external jugular vein (n = 6) using a 29-gauge insulin syringe. Each neonatal mouse received a total volume of 0.1 ml containing 2 × 10 12 vg. 16 For intravenous injections, a microscope was used to visualize the external jugular vein. The needle was inserted into the vein and the plunger was manually depressed. Correct injection was verified by noting blanching of the vein. All injected mice were viable throughout the 15-month period without adverse effect of injection.
Determination of ASA concentrations
Each organ of interest was homogenized in pure water, after which the human ASA concentration was determined using an indirect sandwich enzyme-linked immune sorbent assay. 36 Human ASA do not cross-react with murine ASA.
Immunohistochemistry
Immunohistochemical analysis of neuronal cells was performed as described previously. 16 Mice (n = 6) were anesthetized and then perfused with phosphate-buffered saline followed by 4% paraformaldehyde. Their brains were then dissected out, fixed again overnight at 4°C and immersed in phosphate-buffered saline containing 20% sucrose. Thereafter, they were placed in optimal cutting temperature compound (Tissue-Tek, Tokyo, Japan), and tissue sections were cut to a thickness of 20 μm and mounted on glass slides. The sections were then immunostained for ASA, neurons, cholinergic neurons and GFP by incubation for 16 h at 4°C with goat anti-ASA (5 μg ml -1 , R&D, Minneapolis, MN, USA), mouse anti-NeuN (1:500; Millipore, Billerica, MA, USA), goat anti-choline acetyltransferase (1:100; Millipore) and rabbit anti-GFP (1:1000; Invitrogen, Life Technologies Corp., Carlsbad, CA, USA) antibodies, respectively. After washing the sections three times with phosphate-buffered saline, they were stained with Alexa Fluor 568-conjugated anti-mouse or anti-goat immunoglobulin G (1:500; Invitrogen) or Alexa Fluor 488-conjugated anti-rabbit immunoglobulin G (1:500; Invitrogen). Finally, the sections were examined using a BX60 microscope (Olympus, Tokyo, Japan).
Alcian blue staining and analysis of Sulf and GalC
To detect the accumulation of Sulfs, brain and SC sections were stained with Alcian blue (Sigma-Aldrich, St Louis, MO, USA) as described previously. 40 Briefly, 20-μm frozen sagittal sections were stained with Alcian blue (Sigma-Aldrich; 0.05% in 0.025 M sodium acetate buffer, pH 5.7, containing 0.3 M MgCl 2 and 1% PFA), rinsed in the same buffer without dye and mounted. Sulfs were extracted from organs and purified essentially as described. 41 Briefly, lipids were successively extracted with mixtures of chloroform/methanol (2/1, vol/vol), chloroform/methanol (1/1, vol/vol) and chloroform/methanol/ water (86/14/1, vol/vol/vol). Glycosphingolipids recovered in Folch's lower phase were dried under a stream of nitrogen and then treated with mild alkaline (0.1 M NaOH in methanol) at 40°C for 1 h. After neutralizing the solution with 1 M acetic acid, glycosphingolipids were again recovered in Folch's lower phase and then applied to precoated high-performance thin-layer chromatography-silica gel 60F254 plates (100 × 200 mm 2 , Art. 13728; E Merck, Darmstadt, Germany). The developing solvent used was chloroform/methanol/water (70/30/4, vol/ vol/vol). After development, high-performance thin-layer chromatography plates were spread with 10% (w/v) cupric sulfate hydrate in 8% (v/v) phosphoric acid solution, then charred at 180°C for 10 min. Amounts of Sulfs and GalC present were quantitatively determined by densitometric scanning using an DT-20 MCP image saver (Atto, Tokyo, Japan) as described previously. 9, 12 Data are expressed as mean ± s.e. of Sulf/GalC ratios.
Behavior test
Motor coordination and balance were assessed in the mice (untreated n = 14, ssASA9/AAV n = 6, WT n = 6) by measuring their ability to traverse a graded series of narrow beams to reach an enclosed safety platform. 42 The beams consisted of long (1 m) stainless steel rods (O'Hara & Co. Ltd, Tokyo, Japan), starting at a cross-sectional diameter of 20 mm. Each beam was placed horizontally, 50 cm above the bench surface, with one end mounted on a narrow support and the other end attached to an enclosed box (20 cm 2 ), into which the mouse could escape. The mice were trained to traverse the beam to the enclosed box. Once the mice were trained (traversed the 20 mm diameter), and then they received three trials on each of the round beam. The time required to traverse each beam ('latency') and the number of times the hind feet slipped off a beam ('slips') were recorded for each trial. Analysis of each measure was based on the mean scores of three trials.
Statistical analyses
Results are expressed as means ± s.e. of duplicate or more data obtained from three or more independent experiments. Data were analyzed using two-tailed Student's t-tests. Values of Po0.05 were considered significant.
